PRME

Prime Medicine, Inc.

A biotechnology company developing "Prime Editing," a gene-editing technology that acts like a molecular word processor, able to search for and rewrite faulty DNA without cutting both strands like earlier CRISPR "scissors." Founded in 2019, Prime Medicine aims to turn this science into one-time treatments for serious inherited diseases, and its lead therapy targets chronic granulomatous disease, a rare immune disorder. The company takes its name from the Prime Editing technology it was built around.